Biopharmaceutical company focusing on hard-to-treat cancers Xenetic Biosciences is adding Allan Tsung, MD, to its scientific advisory board.
Dr. Tsung specializes in laparoscopic and robotic surgery. He focuses on caring for patients with liver, bile duct and pancreas cancers, according to the Oct. 4 Xenetic news release.
Dr. Tsung currently serves as the chair of the department of surgery at the Charlottesville-based University of Virginia School of Medicine. He earned his medical degree at Brooklyn, N.Y.-based SUNY Health Science Center.
"Dr. Tsung brings decades of experience across both research and patient care which provides a valuable perspective to our team and significant insight as we advance our innovative immune-oncology technologies, Xenetic CEO Jeffery Eisenberg said. "We remain committed to driving our DNase-based oncology platform forward, and we expect Dr. Tsung to be a key contributor to Xenetic in identifying unmet medical needs and creating pre-clinical and clinical development strategies. We are excited to leverage Dr. Tsung's expertise and continue building momentum."